Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in a higher proportion of patients with at least a very good partial response as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2023-01, Vol.24 (1), p.64-76
Hauptverfasser:	Mina, Roberto, Musto, Pellegrino, Rota-Scalabrini, Delia, Paris, Laura, Gamberi, Barbara, Palmas, Angelo, Aquino, Sara, de Fabritiis, Paolo, Giuliani, Nicola, De Rosa, Luca, Gozzetti, Alessandro, Cellini, Claudia, Bertamini, Luca, Capra, Andrea, Oddolo, Daniela, Vincelli, Iolanda Donatella, Ronconi, Sonia, Pavone, Vincenzo, Pescosta, Norbert, Cea, Michele, Fioritoni, Francesca, Ballanti, Stelvio, Grasso, Mariella, Zamagni, Elena, Belotti, Angelo, Boccadoro, Mario, Gay, Francesca
Format:	Artikel
Sprache:	eng
Schlagworte:	Angina pectoris Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Bone marrow Cardiovascular disease Cyclophosphamide Cyclophosphamide - therapeutic use Cytogenetic Analysis Cytogenetics Death Dexamethasone Drug dosages Female Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans Hybridization Immunotherapy Inhibitor drugs Intolerance Lenalidomide Male Medical prognosis Melphalan Minimal residual disease Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - genetics Neoplasm, Residual Oral administration Patients Stem cell transplantation Targeted cancer therapy Transplantation, Autologous - methods Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!